Skip to main content
. 2014 Jun 10;171(13):3182–3195. doi: 10.1111/bph.12659

Figure 4.

Figure 4

Effect of Bax or p21 knockout on ABT-263 and sorafenib combination-induced apoptosis. (A) Cell viability was assessed in the HCT116 Bax-/- and HCT116 WT cells after the combination treatment of 0.2 μM ABT-263 and 6 μM sorafenib for 24 h. (B) Cell apoptosis was determined via FACS analysis by PI staining, and counting the percentage of cells in the sub-G1 phase. (C) Cell viability was determined with HCT116 p21-/- and HCT116 WT cells after the combination treatment of 0.2 μM ABT-263 and 6 μM sorafenib for 24 h. (D) Cell apoptosis was assessed via FACS. (E) Analysis of PARP, pro-caspase-3, caspase-8, caspsse-9 via Western blot. **P < 0.01.